Investment research on quoted companies and funds

Hardman & Co

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Research from Hardman & Co, Hardman & Co

Research from Hardman & Co

Thematic (Sector/Industry)

United kingdom Financials / Thematic (Sector/Industry)

<ul>
<li>An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database.</li>
<li>This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024.</li>
<li>The year was characterised by 9.2% underlying (ex-COVID-19) growth.</li>
</ul>


An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database.
This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024.
The year was characterised by 9.2% underlying (ex-COVID-19) growth.


Hardman & Co Insight: 2024 Pharma Statistics